Newsroom

Sorted by: Latest

-

Murchinson Invites Fellow Nano Dimension Shareholders to Participate In a Survey: What Trendy Industry Is the Board, Under Chairman Bob Pons' Leadership, Planning to Chase Next?

TORONTO--(BUSINESS WIRE)--Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, “Murchinson” or “we”), a significant shareholder with approximately 7.4% of the outstanding shares of Nano Dimension Ltd. (NASDAQ: NNDM) (“Nano” or the “Company”), today issued the following letter to Nano shareholders. *** Fellow Nano Shareholders, Over the last few weeks and months, we have heard CEO Dave Stehlin repeatedly say that Nano’s Board of Directors (the “Board”), led...
-

ビザ、「Visa Payments Forum」でインテリジェントかつプログラマブルなコマースを支えるAI、ステーブルコイン、トークン分野の新たなイノベーションを発表

サンフランシスコ--(BUSINESS WIRE)--(ビジネスワイヤ) -- Visa Payments Forum 2026で、ビザ(NYSE:V)は、顧客が次世代のコマースを実現できるよう支援するために設計された、AI、ステーブルコイン、トークンの新たな機能を発表しました。これらのイノベーションには、ますます高速化、自動化、インテリジェント化するコマース体験に合わせて、信頼、セキュリティー、コントロールも進化させるというシンプルな目標が反映されています。 基調講演では、ビザの最高製品・戦略責任者であるジャック・フォレステルが、人工知能とステーブルコインという2つの根本的な変化が、資金移動のフロントエンドとバックエンドの双方をどのように変革しているか、また、顧客がこうした変革に参画できるようビザがどのように支援しているかを説明しました。 フォレステルは、次のように述べました。「AIはコマースのフロントエンドを変革しています。ステーブルコインはバックエンドを再構築しています。ビザの役割は、エコシステムのすべての参加者にとって、こうした仕組みが安全かつ確実に、グローバル規模で機能する...
-

Gregory & Appel Welcomes Matt Heincker as Employee Benefits Practice Leader

INDIANAPOLIS--(BUSINESS WIRE)--Gregory & Appel Insurance (G&A), a fiercely independent insurance and risk management advisor, announced that Matt Heincker has joined the organization as Employee Benefits Practice Leader. In his role, Heincker will help lead the growth of the Employee Benefits practice while developing a high-performing team of consultants who deliver a superior client experience. Heincker brings nearly 20 years of experience in employee benefits brokerage and leadership...
-

Samenvatting: Visa kondigt tijdens het Visa Payments Forum nieuwe innovaties aan op het gebied van AI, stablecoins en tokens om intelligente, programmeerbare handel mogelijk te maken

SAN FRANCISCO--(BUSINESS WIRE)--Tijdens het Visa Payments Forum 2026 heeft Visa (NYSE: V) vandaag nieuwe mogelijkheden op het gebied van AI, stablecoins en tokens aangekondigd. Met deze innovaties wil het bedrijf klanten helpen de volgende generatie van e-commerce te realiseren. Deze innovaties hebben één duidelijk doel: ervoor zorgen dat vertrouwen, veiligheid en controle gelijke tred houden met de steeds snellere, geautomatiseerde en slimmere e-commerce-ervaringen. In een keynote-presentatie...
-

Securities Fraud Investigation Into Erasca, Inc. (ERAS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ERASCA, INC. (ERAS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On April 27, 2026, before market hours, Erasca disclosed that it had received a...
-

Riassunto: Curatis aumenta le prospettive di crescita dei ricavi per il 2026

LIESTAL, Svizzera--(BUSINESS WIRE)--Curatis Holding AG (SIX: CURN) aumenta le prospettive di crescita dei ricavi per l'esercizio 2026: la società prevede un aumento dei ricavi pari a circa il 40% nel 2026, a differenza delle precedenti previsioni di oltre il 25%. Sulla base di figure preliminari per i primi cinque mesi del 2026, Curatis prevede un aumento dei ricavi significativamente superiore alle previsioni per il 2026. L'aumento del fatturato è trainato da prodotti che Curatis commercia da...
-

Securities Fraud Investigation Into PDD Holdings Inc. (PDD) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of PDD Holdings Inc. (“PDD” or the “Company”) (NASDAQ: PDD) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON PDD HOLDINGS INC. (PDD), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On January 19, 2026, Bloomberg reported that China had broadened its probe...
-

Riassunto: Al Visa Payments Forum Visa annuncia varie innovazioni legate all’IA, alle stablecoin e ai token per dare impulso al commercio intelligente e programmabile

SAN FRANCISCO--(BUSINESS WIRE)--In occasione del Visa Payments Forum 2026, Visa (NYSE: V) oggi ha annunciato nuove funzionalità riguardanti l’IA, le stablecoin e i token, studiate per aiutare i clienti a promuovere la nuova generazione del commercio. Queste innovazioni rispecchiano un obiettivo semplice: garantire che fiducia, sicurezza e controllo evolvano di pari passo con esperienze commerciali sempre più rapide, automatizzate e intelligenti. Nel suo intervento di apertura Jack Forestell, Di...
-

BeOne apresenta dados históricos da Fase 3 em pacientes com LLC com mais de 80 anos na EHA 2026, reforçando os benefícios do BRUKINSA

SAN CARLOS, Calif.--(BUSINESS WIRE)--A BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), empresa global de oncologia, anunciou hoje a apresentação de um amplo conjunto de dados da Fase 3 em pacientes com leucemia linfocítica crônica (LLC) ou linfoma linfocítico de células pequenas (LLCP) com 80 anos ou mais. Os dados mostram benefício sustentado com o uso de BRUKINSA após quase 6,5 anos de acompanhamento, reforçando seu papel como inibidor de BTK fundamental. O BRUKINSA é o único in...
-

Riassunto: BeOne presenta dati fondamentali di Fase 3 di pazienti affetti da CLL di età superiore agli 80 anni in occasione di EHA 2026, ribadendo il vantaggio di BRUKINSA

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), una società globale operativa in ambito oncologico, ha annunciato oggi la presentazione di un vasto dataset di Fase 3 in pazienti affetti da leucemia linfocitica cronica o linfoma linfocitario a piccole cellule (CLL/SLL) di età pari o superiore agli 80 anni, da cui è emerso un beneficio duraturo con BRUKINSA dopo quasi 6,5 anni di follow-up, che ribadisce il suo ruolo di inibitore fondamentale del...